A simple method for quantifying functional selectivity and agonist bias.

Activation of seven-transmembrane (7TM) receptors by agonists does not always lead to uniform activation of all signaling pathways mediated by a given receptor. Relative to other ligands, many agonists are "biased" toward producing subsets of receptor behaviors. A hallmark of such "functional selectivity" is cell type dependence; this poses a particular problem for the profiling of agonists in whole cell test systems removed from the therapeutic one(s). Such response-specific cell-based variability makes it difficult to guide medicinal chemistry efforts aimed at identifying and optimizing therapeutically meaningful agonist bias. For this reason, we present a scale, based on the Black and Leff operational model, that contains the key elements required to describe 7TM agonism, namely, affinity (K(A) (-1)) for the receptor and efficacy (τ) in activating a particular signaling pathway. Utilizing a "transduction coefficient" term, log(τ/K(A)), this scale can statistically evaluate selective agonist effects in a manner that can theoretically inform structure-activity studies and/or drug candidate selection matrices. The bias of four chemokines for CCR5-mediated inositol phosphate production versus internalization is quantified to illustrate the practical application of this method. The independence of this method with respect to receptor density and the calculation of statistical estimates of confidence of differences are specifically discussed.

[1]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[2]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[3]  J S Ward,et al.  Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles. , 1995, Journal of medicinal chemistry.

[4]  R P STEPHENSON,et al.  A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.

[5]  Terry Kenakin,et al.  Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. , 2007, Trends in pharmacological sciences.

[6]  Sadashiva S Karnik,et al.  Multiple Signaling States of G-Protein-Coupled Receptors , 2005, Pharmacological Reviews.

[7]  Clay W Scott,et al.  Evaluating Cellular Impedance Assays for Detection of GPCR Pleiotropic Signaling and Functional Selectivity , 2009, Journal of biomolecular screening.

[8]  Terry Kenakin,et al.  Drug efficacy at G protein-coupled receptors. , 2002, Annual review of pharmacology and toxicology.

[9]  R. Zimlichman,,et al.  Pharmacological basis for functional selectivity of partial muscarinic receptor agonists. , 1996, European journal of pharmacology.

[10]  M. Bouvier,et al.  Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy , 2006, Molecular Pharmacology.

[11]  H. Rang STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLE. , 1964, British journal of pharmacology and chemotherapy.

[12]  B. Roth,et al.  Multiple mechanisms of serotonergic signal transduction. , 1987, Life sciences.

[13]  T. Kenakin '7TM receptor allostery: putting numbers to shapeshifting proteins. , 2009, Trends in pharmacological sciences.

[14]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[15]  Qin Wang,et al.  Regulation of α2AR trafficking and signaling by interacting proteins , 2007 .

[16]  Arthur Christopoulos,et al.  Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias* , 2010, The Journal of Biological Chemistry.

[17]  John P. Moore,et al.  Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. , 2007, Virology.

[18]  J. Violin,et al.  β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .

[19]  R. Mailman GPCR functional selectivity has therapeutic impact. , 2007, Trends in pharmacological sciences.

[20]  Thomas A Kost,et al.  Implementation of BacMam virus gene delivery technology in a drug discovery setting. , 2007, Drug discovery today.

[21]  G. Milligan,et al.  Deconvolution of complex G protein–coupled receptor signaling in live cells using dynamic mass redistribution measurements , 2010, Nature Biotechnology.

[22]  David R. Sibley,et al.  Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.

[23]  F. Ehlert Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[25]  R. Lefkowitz,et al.  Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor Receptor* , 2009, Journal of Biological Chemistry.

[26]  J. Black,et al.  An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation , 1985, British journal of pharmacology.

[27]  H. Loh,et al.  Interaction of delta-opioid receptors with multiple G proteins: a non-relationship between agonist potency to inhibit adenylyl cyclase and to activate G proteins. , 1994, Molecular pharmacology.

[28]  F. Ehlert,et al.  Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes , 2009, Journal of Pharmacology and Experimental Therapeutics.

[29]  Terry Kenakin,et al.  Efficacy at g-protein-coupled receptors , 2002, Nature Reviews Drug Discovery.

[30]  L. Luttrell Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity , 2007, Journal of Molecular Neuroscience.

[31]  L. Limbird,et al.  G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. , 2002, Cellular signalling.

[32]  P. Sexton,et al.  G‐Protein‐coupled receptor–protein interactions: Basis for new concepts on receptor structure and function , 2005, Clinical and experimental pharmacology & physiology.

[33]  C. Breivogel,et al.  Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. , 2000, Molecular pharmacology.

[34]  M. Matsui,et al.  Estimation of Relative Microscopic Affinity Constants of Agonists for the Active State of the Receptor in Functional Studies on M2 and M3 Muscarinic Receptors , 2009, Molecular Pharmacology.

[35]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.